This study is currently not recruiting participants.

A Randomized Double-Blind Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation

Study on the Effectiveness of Adding Investigational Medication to Steroids for Idiopathic Pneumonia Syndrome (a lung condition with unknown cause)

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to find out whether adding etanercept to a commonly used treatment for IPS (steroids) is more effective in treating Idiopathic Pneumonia Syndrome than steroids alone.

Detailed description of study

The purpose of this study is to find out whether adding etanercept to a commonly used treatment for IPS (steroids) is more effective in treating Idiopathic Pneumonia Syndrome than steroids alone.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Non-Infectious Pulmonary Dysfunction, Idiopathic Pneumonia Syndrome
  • Age: 18 years - 100 years
  • Gender: All

The purpose of this study is to find out whether adding an investigational medication to a commonly used treatment for Idiopathic Pneumonia Syndrome (IPS), which is a lung condition with unknown cause, is more effective than using steroids alone.

Participants will receive either the investigational medication added to steroids or steroids alone. The study will compare the outcomes to see which approach is more effective.

  • Who can participate: Participants aged 18 and older with a diagnosis of Idiopathic Pneumonia Syndrome are eligible. Other criteria include no prior treatment with the investigational medication and no severe comorbid conditions.
  • Study details: Participants will be assigned to receive either the investigational medication with steroids or steroids alone. A placebo is not mentioned in the study details.
Updated on 19 Feb 2024. Study ID: 1105005633

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team